Type 1 Diabetes Management Beyond Insulin: Aligning Evidence, Research, and Regulation
Endocrinology and Metabolism Clinics of North America · 2026-09 · 55 (3) · xv-xix
DOI: 10.1016/j.ecl.2026.04.016 ↗Kurz gefasst
Editorial in der Zeitschrift Endocrinology and Metabolism Clinics of North America, 2026-09. Verfasst von Courtney A Ackeifi und 1 weiteren Autor:innen. Beteiligte Einrichtung: Breakthrough T1D, New York, NY, USA. Electronic address: cackeifi@breakthrought1d.org. Die Arbeit nennt 9 Literaturangaben. Gefördert von: Medtronic, Cystic Fibrosis Foundation, Eli Lilly and Company.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Kein Abstract verfügbar.
Autor:innen und Institutionen
- Breakthrough T1D, New York, NY, USA. Electronic address: cackeifi@breakthrought1d.org.
- Division of Endocrinology and Metabolism, Indiana University School of Medicine, Indianapolis, IN, USA. Electronic address: shahvi@iu.edu.
Förderung
- Medtronic
- Cystic Fibrosis Foundation
- Eli Lilly and Company
- National Institutes of Health
Zitieren
APA
Ackeifi, C. A., & Shah, V. N. (2026). Type 1 Diabetes Management Beyond Insulin: Aligning Evidence, Research, and Regulation. Endocrinology and Metabolism Clinics of North America, 55(3), xv-xix. https://doi.org/10.1016/j.ecl.2026.04.016
Vancouver
Ackeifi CA, Shah VN. Type 1 Diabetes Management Beyond Insulin: Aligning Evidence, Research, and Regulation. Endocrinology and Metabolism Clinics of North America. 2026;55(3):xv-xix. doi:10.1016/j.ecl.2026.04.016
BibTeX
@article{Ackeifi2026,
author = {Ackeifi, Courtney A and Shah, Viral N},
title = {Type 1 Diabetes Management Beyond Insulin: Aligning Evidence, Research, and Regulation},
journal = {Endocrinology and Metabolism Clinics of North America},
year = {2026},
volume = {55},
number = {3},
pages = {xv--xix},
doi = {10.1016/j.ecl.2026.04.016}
}
EUVIMED